Natural killer immunity and the cancer immunome
Natural killer immunity and the cancer immunome
Novel strategy could help overcome resistance to radiotherapy in metastatic melanoma
Interim WINTHER study findings provide lessons for future research
Banking on biomarkers – improving the diagnosis of early stage NSCLC
How can a systems biology approach aid precision cancer medicine?
Personalised, genomic-guided combination therapy could transform early disease management in ovarian and breast cancer
What can T-cells see on human cancer?
Moving precision medicine for lung cancer into the adjuvant setting
From innovation to improved patient care: challenges for foundations and cancer research organisations
Methodology certification and accreditations to perform assays
WIN Symposium 2015 highlights
Next generation of trials with targeted agents
The importance of target expression in personalised medicine
Taking biopsies in clinical trials: The WINTHER laboratory experience
Radiation and immunology – a new therapeutic partnership
Meta-analysis confirms benefits and safety of precision medicine
SPRING – rolling tri-therapy combinations of targeted drugs in second line of metastatic NSCLC
TargomiRs show promise in phase I study of malignant mesothelioma
SPECTAlung: improving clinical trial access for patients with thoracic tumours
Cancer genomics of urothelial cancer and fibroepithelial tumors of the breast
WIN 2015 hosts 'world class leaders' in personalised therapy
WIN 2015: Oncologists and industry working together for personalised medicine